Dr. J. Donald Debethizy

Biography

 Dr. J. Donald deBethizy has had thirty years of experience in the biotechnology and consumer products industry. He has served as president and chief executive officer of Santaris Pharma A/S, Denmark and U.S., until September 2014, when the company was sold to Roche. He served as executive chairman of Contera Pharma ApS until it was sold to Bukwang Pharma in November 2014. He also served as Chairman of the Board of immuno-oncology company Rigontec GmbH until its acquisition by MSD in September 2017 and Board member of Serendex Pharmaceuticals A/S (Oslo Stock Exchange) until its acquisition by Savara Pharmaceuticals. Don was co-founder and chief executive officer of Targacept, Inc., U.S., a public biotechnology company listed on NASDAQ. He completed a postdoctoral fellowship at the Chemical Industry Institute of Toxicology at Research Triangle Park, NC. Dr. deBethizy has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University. He is currently President of White City Consulting ApS in Denmark and serves on the supervisory Boards of arGEN-X NV (Euronext Brussels/NASDAQ), Newron Pharmaceuticals S.P.A. (SIX Swiss Exchange), Proterris and Albumedix.

Research Interest

 oncology